Pfizer Inc. (NYSE:PFE) is one of the most active US stocks to buy right now. On April 28, Pfizer entered into settlement ...

The pharmaceutical giant just extended the lifespan of one of its top drugs.

Pfizer has reached agreements with Dexcel Pharma, Hikma Pharmaceuticals and Cipla, regarding lawsuits filed in the U.S.

The settlements delay the entry of generic copies of Pfizer’s Vyndamax by almost three years, stabilizing sales of a drug ...

Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.

Pfizer Inc. (NYSE: PFE) today announced that it has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd, regarding lawsuits filed in ...

As Pfizer gears up to defend its patents on transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis in court this week, ...

Pfizer Inc. announced that it has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd, regarding lawsuits filed in the US District ...

Pfizer inking the last of three settlements to postpone copycats to its transthyretin amyloid cardiomyopathy (ATTR-CM) med ...

On April 28, Morgan Stanley reiterated an Equal Weight rating on Pfizer Inc. (NYSE:PFE). It also set a $28 price target on ...

Pfizer Inc.'s agreements dropping two generic-drug makers from a patent case over copies of its blockbuster heart drug Vyndamax left Hikma Pharmaceuticals Plc the last remaining defendant for a bench ...